Cancer Advisor

Medically Reviewed by: OneDayMD Editorial Team | Written by:     Dr Frank Yap, MD | Last Updated: August  2026 Quick Answer The most consequential 2026 cancer breakthrough is daraxonrasib , an oral RAS(ON) inhibitor that nearly doubled overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial presented at ASCO 2026. Other major advances include the OPTIMA trial , showing many high-risk breast cancer patients can safely skip chemotherapy after genomic testing; the bispecific antibody ivonescimab , which outperformed standard immunotherapy in squamous lung cancer; continued expansion of CAR-T and cell therapies into solid tumors; and growing, evidence-tiered interest in repurposed drugs and metabolic approaches as complementary strategies. AACR 2026 and ASCO 2026 both emphasized that progress is driven by combining precision diagnostics, immunotherapy, and targeted agents — not a single cure. Cancer remain...

OneDayMD Oncology Intelligence • 2026 Update From Keytruda and CAR-T to antibody-drug conjugates, radioligand therapy and Gendicine gene therapy. Reviewed/updated: September 2026 The global cancer-treatment industry is entering a new era. Oncology is no longer defined simply by chemotherapy and conventional small-molecule drugs. The modern cancer-treatment ecosystem includes immune checkpoint inhibitors, targeted therapies, antibody-drug conjugates (ADCs), bispecific antibodies, CAR-T cells, radioligand therapies, protein degraders, cancer vaccines, oncolytic viruses and gene therapies. This updated 2026 review therefore looks beyond a simple sales ranking. It evaluates the world's leading cancer-drug and biotechnology companies according to oncology commercial scale, therapeutic innovation, pipeline strength, platform technology, strategic importance and potential influence on the future of cancer treatment . Key takeaway: ...